+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol

Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol

Allergology International 62(1): 131-135

Nebulized drugs for asthma treatment are often mixed together in order to simplify inhalation regimens, although not recommended. We therefore evaluated aerosol characteristics and physicochemical stability of the admixture of an inhaled corticosteroid suspension with a beta2-agonist solution. An 8-stage cascade impactor was used to measure the particle size distribution of admixture of Pulmicort® Respules® (budesonide, 0.5mg/2mL) with Meptin® Inhalation Solution Unit (procaterol hydrochloride, 30μg/0.3mL) from a jet nebulizer, PARI LC Plus®. Concentration of each drug was assayed with high-pressure liquid chromatography. Physicochemical compatibility was also assessed up to 24 hours after mixing. With regard to budesonide, impactor parameters such as mass median aerodynamic diameter (MMAD) and respirable mass (RM) were comparable between admixtures and single-drug preparations (2.92 ± 0.03 vs 2.99 ± 0.14μm, 146.8 ± 2.9 vs 147.6 ± 8.2μg, respectively). On the other hand, delivery rates of procaterol increased when admixed with budesonide suspension, resulting in significantly higher RM (15.1 ± 0.8 vs 10.2 ± 0.5μg, p < 0.01). Variations from initial concentration in the percentages of drug remaining at any time point were less than 10%, and there were no appreciable changes in pH of the admixtures for up to 24 hours. There is a possibility that admixture might influence of aerodynamic characteristics of procaterol, but not budesonide. In vivo data will be needed for the clinical implications of our findings.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 051406182

Download citation: RISBibTeXText

PMID: 23348859

Related references

Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. Journal of Asthma 47(4): 447-459, 2010

Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. Budesonide Inhalation Suspension Study Group. Journal of Allergy and Clinical Immunology 104(4 Pt 2): 191-199, 1999

A comparison of the protective effect of procaterol aerosol and procaterol tablet on bronchoconstriction induced by methacholine inhalation. Current Therapeutic Research 40(3): 624-633, 1986

Comparison of the Efficacy of Budesonide Nebulizer Suspension and Budesonide Inhalation Suspension in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Tanaffos 17(2): 96-102, 2019

Alterations in blood levels of carbohydrate and lipid metabolites and of cyclic AMP mediated by beta1- and beta2-adrenoceptors in beagle dogs: effects of procaterol, a new selective beta2-adrenoceptor agonist. European Journal of Pharmacology 53(4): 351-358, 1979

A Novel Submicron Formulation of Nebulized Budesonide Significantly Improves the Fine Particle Fraction of Drug Available for Inhalation From Various Jet Nebulizers Compared to a Marketed Budesonide Suspension. Journal of Allergy and Clinical Immunology 123(2): S156-S156, 2009

Synthesis and evaluation of procaterol, a selective agonist for detection of pulmonary beta2-adrenoceptors with PET. Journal of Nuclear Medicine 40(5 SUPPL ): 123P, 1999

Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. Applied Radiation and Isotopes 52(4): 857-863, 2000

Therapy with nebulized beta2 agonists (procaterol) in asthmatic children: pulmonary function and plasma levels after inhalation. Arerugi 56(11): 1372-1377, 2007

Pharmacological and clinical profile of Budesonide inhalation suspension (Pulmicort inhalation liquid), an inhaled steroid drug for asthma. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 129(3): 197-207, 2007

A new aerosol adrenergic bronchodilator, procaterol. Comparative study of salbutamol and procaterol. L'Union Medicale du Canada 116(4): 215-218, 1987

Effect of procaterol in dosed aerosol and the procaterol-theophylline combination. Archivio Monaldi Per le Malattie del Torace 44(4-6): 825, 1989

Medicinal inhalation aerosol formulations containing budesonide. Official Gazette of the United States Patent & Trademark Office Patents 1232(3), Mar 21, 2000

Role of budesonide inhalation suspension in children with asthma. Annals of PharmacoTherapy 36(2): 322-325, 2002

Compatibility of budesonide inhalation suspension with four nebulizing solutions. Annals of PharmacoTherapy 38(6): 967-972, 2004